Topic starter
There is a new scientific article that investigates how acute and chronic treatment with fluoxetine influences the behavioral effects of psychedelics in mice.
In it, we discuss:
The researchers used the head-twitch response, a commonly used behavioral measure of 5-HT2A activation in rodents, to test how SSRI treatment alters sensitivity to psychedelics. This is relevant because SSRIs are often used for the same conditions for which psychedelic therapy is now also being investigated.
The real focus of this article is not on therapeutic outcomes in humans, but on a preclinical model that provides insight into possible interactions between antidepressants and psychedelics. The authors examined acute fluoxetine, chronic fluoxetine, and a period after discontinuation of fluoxetine, and compared the response to DOI and psilocybin.
The results show that a single acute dose of fluoxetine at 10 mg/kg had no effect on the DOI-induced head-twitch response. In contrast, chronic fluoxetine at 10 mg/kg for 14 days resulted in a downward shift of the DOI dose-response function, indicating that behavioral sensitivity to DOI decreased. After a 14-day discontinuation period, this effect disappeared, suggesting that this adjustment is reversible.
For psilocybin, the authors found something different. Acute fluoxetine at 10 mg/kg reduced the effectiveness of psilocybin but did not change the potency. According to the authors, this suggests that interactions between SSRIs and psychedelics may be substance-specific and therefore do not necessarily have the same outcome for every psychedelic substance.
It is important to note, however, that this study was conducted entirely in male mice. Therefore, the article says nothing directly about clinical effectiveness or about what exactly patients using fluoxetine can expect from psychedelic treatment. It primarily provides a biological signal that SSRI history can alter the response to psychedelics.
In one sentence: this article shows that chronic fluoxetine attenuates the behavioral response to DOI in mice, that this effect may disappear after discontinuation, and that acute fluoxetine can also reduce the effectiveness of psilocybin.
Spoiler
New article description
Abstract
Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed for mood and anxiety disorders, the same conditions under which psychedelic-assisted therapies are gaining renewed interest. However, it remains unclear how SSRI treatment may influence sensitivity to psychedelics, particularly through the shared engagement of serotonergic pathways.
Here, we used the head-twitch response (HTR), a well-established behavioral readout of 5-HT2A activation, to investigate how acute, chronic, and discontinued fluoxetine treatment modulates the behavioral effects of R(-)-DOI and psilocybin, where psilocybin was only evaluated in the acute fluoxetine paradigm. In male mice, acute fluoxetine at 10 mg/kg had no effect on DOI-induced HTR, whereas chronic fluoxetine (10 mg/kg for 14 days) produced a downward shift in the DOI dose-response function.
This attenuated response following a 14 day discontinuation period was reversed, suggesting that the behavioral consequences of chronic SSRI exposure may return following cessation. Interestingly, acute 10 mg/kg fluoxetine attenuated the efficacy, but not potency, of psilocybin, suggesting that SSRI-psychedelic interactions may vary depending on the pharmacological properties of the psychedelic compound.
Together, these findings demonstrate that SSRI treatment history can alter the behavioral efficacy of psychedelics in a way that may be compound specific. These results have important implications for psychedelic-assisted therapies in populations taking SSRIs and highlight the need for translational studies to inform cotreatment strategies and guide clinical trial design.
Keywords: Fluoxetine; SSRI; psilocybin; DOI; head twitch response; 5-HT2A; mice; psychedelics.
Posted : 19 March 2026 18:20